These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29465554)

  • 41. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
    Dayyani F; Kantarjian H; O'Brien S; Pierce S; Jones D; Faderl S; Garcia-Manero G; Cortes J; Ravandi F
    Cancer; 2011 Jan; 117(1):110-5. PubMed ID: 20803607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
    Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
    Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
    Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
    Nayak S; Shen M; Bunaciu RP; Bloom SE; Varner JD; Yen A
    Leuk Lymphoma; 2010 Sep; 51(9):1734-47. PubMed ID: 20615082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
    Zeidan AM; Gore SD
    Clin Cancer Res; 2014 Oct; 20(19):4985-93. PubMed ID: 25274377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
    Jing Y; Waxman S
    Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center.
    Saxena M; Madabhavi IV; Patel A; Panchal H; Anand A
    J Cancer Res Ther; 2023; 19(5):1371-1378. PubMed ID: 37787311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
    Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M; Foà R
    Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
    Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.